Overview

We are focused on developing and commercializing drugs that treat very serious lung infections in orphan disease populations.

Investment Thesis

Our lead product candidate, ARIKACE, has multiple clinical and patient benefits.

• Proprietary inhaled liposomal formulation of the antibiotic amikacin, an FDA-approved aminoglycoside that is currently delivered intravenously
• Engineered to deliver amikacin directly to the site of serious lung infections
• Potential for improvements to the conventional inhalation methods of delivering drug to the pulmonary system

We have two near-term commercial opportunities in orphan lung diseases.

• Europe: ARIKACE Phase 3 trial to treat CF patients with Pseudomonas lung infections enrollment completed
• US: ARIKACE Phase 2 trial to treat NTM enrollment well underway. Potential accelerated path to approval

We have near-term value-driving milestones.

• Phase 3 CF-related Pseudomonas lung infection data expected in mid-2013
• Phase 2b NTM lung infection data expected by year end 2013

 We have a solid and broad IP portfolio.

• More than a decade of investment in research and development

• Potential coverage into 2029

 We are well-capitalized and are building out our infrastructure.

• $91.9 million in cash (as of September 30, 2012)

View all »   News Releases

May 14, 2013
Insmed Granted Key Composition of Matter Patent Allowance for ARIKACE in Europe

May 13, 2013
Insmed to Present at the UBS Global Healthcare Conference

View all »Events

May 20, 2013
Insmed to Present at the UBS Global Healthcare Conference
Listen to webcast

May 16, 2013
Insmed to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Listen to webcast